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Brachytherapy boost may improve local control in very 
young patients treated with breast conservation 
G. van Tienhoven ~, G.M. McColf '2, E.D. Geijsen 1, C.C.E. 
Koning ~ 
~Academic Medical Center, Radiation Oncology, Amsterdam, 
The Netherlands 
2Universitair Medisch Centrum St Radboud, Radiation 
Oncology, Nijmegen, The Netherlands 
Introduction: Very young age is a risk factor for local control in 
breast conservation. To investigate if type of boost treatment 
may influence this, all patients of 40 years or younger treated in 
the Academic Medical Centre (AMC) with long term follow-up 
were analyzed. 
Patients & Methods: Of 83 patients treated between 1986 and 
1998, 5 were lost to follow up (6%). Of the remaining 78 
patients median follow up was 78 months, 54 received a Brachy 
Therapy (BT) boost and 24 an external Beam (EB) boost. BT 
boost was applied using a two plane rigid needle implant during 
operation with open excision wound. Low Dose Rate or Pulsed 
Dose Rate afterloading techniques were used. EB was mainly 
performed using 8-14 MeV Electron beams. The choice for EB 
boost was made mainly for logistic reasons (referral after 
surgery). 
Results: Seventeen (21.8%) patients experienced a local 
recurrence. A local recurrence was observed in 15% (n=8) of 
the BT group and 37.5% (n=9) of the EB group. The crude five- 
year local recurrence rate was 11% (BT) and 16.7% (EB). The 
actuarial local control differed significantly (p=0.03). The 
actuarial 5 year survival rate was 82% in both groups. Cosmetic 
results were comparable in both groups. 
Conclusion: Although these results should be interpreted with 
caution because of the small numbers and possible biases due 
to the retrospective nature of the study, they suggest that long 
term local control may be improved using (intra operative) 
brachytherapy in these very young patients. 
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A randomized study of immediate vs delayed radiotherapy 
in patients receiving CMF chemotherapy after conservative 
surgery for breast cancer 
G. Arcangeli, P. PinnarO, C. Giordano, M. Messina 
Regina Elena Cancer Institute, Radiation Oncology, Roma, Italy 
Introduction: there are still controversies on optimal sequence 
of chemotherapy and radiotherapy in patients who undergo a 
conservative surgery for mammary carcinomas. The purpose of 
this study was to compare two different timing of radiation 
treatment in patients who underwent a conservative surgery 
and who were planned to receive adjuvant CMF chemotherapy. 
Material and methods: a total of 206 patients, operated in our 
Institution of quadrantectomy plus axillary clearance for an 
invasive carcinoma of the breast, in whom six cycles of 
adjuvant CMF (cyciophospbamide 600 mg per square meter i.v. 
on days 1 and 8 of each cycle, methotrexate 40 mg per square 
meter i.v. on days 1 and 8 of each cycle an 5Fu 660 mg per 
square meter i.v. on days 1 and 8, repeated 28 days intervals) 
were previously and independently planned by medical 
oncology, were randomized to receive an immediate (i.e. 
treatment initiated within 2 months from the day of 
quadrantectomy) or a delayed radiotherapy (i.e. treatment 
started within 6 to 7 months from the day of surgery). Patients 
were stratified for age(< 45 yr vs >45yr), pT (T1 vs T2) and pN 
(NO vs N1). All patients began CMF within 2 months from 
surgery. Radiotherapy was delivered only to the whole breast 
by means of tangential fields to a dose of 50Gy in 20 fractions 
in 4 weeks, followed by an electron boost of 10 to 15 Gy in 4 to 
6 fractions to the tumor bed. Inclusion criteria were invasive 
carcinomas of the breast, negative surgical margins, no distant 
metastases, no previous radiotherapy or chemotherapy, 
age<76 years, no previous malignant tumors, written 
consensus. 
Results: all patients completed the planned radiotherapy. No 
evidence of an increased risk of toxicity was observed in the 
immediate radiotherapy with respect to the delayed arm. The 
compliance of the treatment was excellent in both arm groups. 
No difference in radiotherapy duration between the two groups 
was observed. The mean dose-intensity of all drugs was not 
different between the two arms. After a median follow-up of 54 
months, no difference in five-years event-free survival was 
observed in the two groups. 
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Introduction: DCIS has become an increasingly common 
diagnosis fo~owing the advent of mammographic screening. 
Generally, local treatment comprises either simple mastectomy 
alone or complete microscopic tumour excision and 
radiotherapy. Endocrine treatment is usually given to those with 
ER +ve disease. The purpose of the trial is to identify the group 
of patients who can be spared radiotherapy. This trial aims to 
recruit 2000 women who have had complete surgical excision 
of low risk ER positive DClS. All patients will receive adjuvant 
endocrine treatment and will be randomised to observation or 
radiotherapy. 
Methods: Eligible patients will be identified in multi-disciplinary 
meetings. Clinicians will discuss the trial with the patient and a 
dedicated nurse will support the patient and supply additional 
information as necessary. If willing, patients can also take part 
in the biomarker study and /or the quality of life study. In 
centres also taking part in the IBIS II (DClS) trial (blinded study 
of anastrozole versus tamoxifen), patients can be randomised 
to both trials. Patients not eligible for, or not willing to take part 
in, IBIS II (DClS) trial will receive tamoxifen. 
Aims: The primary aim of the trial is to test the effects of 
avoiding radiotherapy in terms of ipsilateral tumour relapse 
(invasive and DClS) and quality of life, following complete 
microscopic tumour excision in the presence of adjuvant 
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systemic endocrine therapy in patients with low-risk ER positive 
DCIS of the breast. Other aims are to identify the minimum 
surgical margins required to prevent local recurrence, and to 
identify molecular markers that predict for ipsilateral tumour 
recurrence with or without radiotherapy. 
Conclusions: It is intended that over 100 centres in the UK, 
together with centres in Ireland, Australia and New Zealand will 
participate in the trial. We anticipate the first centres will start 
recruitment in July 2004. The British Association of Surgical 
Oncology (BASe) and the NCRI Breast and Radiotherapy 
Clinical Studies Groups support the trial and funding has been 
secured from Cancer Research UK. 
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Radiotherapy administration and neutropenic events in five 
European audits of adjuvant breast cancer chemotherapy 
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Background: There are few European data on the risk factors 
and consequences of chemotherapy (CT)-induced neutropenic 
events (NE) in the adjuvant breast cancer setting. The impact of 
breast radiation is rarely addressed in this context. 
Materials and methods: Data from five retrospective European 
audits were combined into a single dataset of individual 
observations. NE were defined as neutropenia-related 
hospitalisation; CT dose reduction > 15%; or CT dose delay > 7 
days. Analysis focused on NE risk factors and on the 
occurrence of low average relative CT dose intensity (ARDI < 
85%). Multivariate adjusted odds ratios (ORs) were calculated 
by robust multiple logistic regression. 
Results: Information on whether CT administration was 
accompanied by concomitant radiotherapy (RT) was available 
for 2'409 patients diagnosed between 1983 and 2001. They had 
a mean age at diagnosis + SD of 51.5 + 11.3 years. They were 
post-menopausal in 52% and hormone receptor positive in 
64%. The spread of disease was 18% stage I, 65% stage il, 
17% stage III. CT regimens were CMF-based in 58%, 
anthracycline-based in 40%, taxane-based in 1% and other 
regimens in 2%. Colony-stimulating factors were used in 12%. 
Any RT was reported in 52%, prior RT in 5%, concomitant RT in 
32%, and subsequent RT in 16%. There was concomitant RT in 
40% of the patients with CMF-based regimens, 22% of those 
with anthracycline-based, 29% of those with taxane-based and 
18% of those with other regimens (p < 0.0005). Seventy 
patients receiving RT within a sandwich schedule, mostly in 
combination with CMF-based CT, were included here. 
NE were seen in 20% of patients. They occurred in 17% of 
those without vs 27% of those with concomitant RT (p < 
0.0005). Logistic regression showed NE to be independently 
associated with concomitant RT; age; number of CT cycles 
planned; cycle duration; and regimen type (Table 1). ARDI < 
85% was seen in 16% of patients. It occurred in 14% of those 
without vs 21% of those with concomitant RT (p < 0.0005). 
Exclusion of the patients with a pre-planned interruption of CT 
did not alter these results. 
Conclusions: Concomitant RT administration was an 
independent risk factor for NE occurrence and impacted 
negatively on CT dose intensity in patients receiving adjuvant 
breast cancer CT. Increased protective measures may be 
required when this risk factor is present. 
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Table 1. Independent influences on NE occurrence 
'(N = 2'260") 
Influence OR (95% CI) p-value 
'Age 1.01 (1.00-1.02)** { 0.021 
Cycle length 0.96 (0.92-1.00) . . . .  ~: 0,045 
Anthracycline-based CT 10.60 ( 0.45-0.81 ) . . . . .  0,001 
Taxane-based CT {1.74 (0.09-1.21) . . . . . .  0.346 
Other CT 0,34 (0.24-1.63) . . . . .  { 0,095 
~,~ ............... N <.~;~-0~ci~ue ~o~.mis~sing.~ ,vaiues s p~ea...d.~overva i, o-u~s 
independent variables 
i * *  Per additional year of age 
=*** Per additional cycle planned 
. . . .  Per additional cycle day ; I 
. . . . .  Compared to CMF-based CT i 
......................................................................................................................................................... ! 
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IORT in breast cancer as boost: preliminary results of a 
pilot randomized study on use of IORT for stage I ° and II ° 
breast cancer 
A. Ciabattonf, G. Fortuna ~, V. Ciccone 1, S. Drago 2, G. Grassi 2, 
R. Consortl ~, A. PetruccP 
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3U.O. Medical Physics, Ospedale S.Filippo Neff 
Introduction: The use of a dedicated mobile linear accelerator 
makes the IORT procedure quicker and easier. To compare the 
efficacy on local control of IORT boost after quadrantectomy 
versus conventional treatment with external electron beam 
boost a randomized study was carried on. Preliminary results in 
terms of local control, esthetic evaluation and toxicity were 
analyzed. 
Methods Since April 1999 a pilot randomized study in women 
with T1-T2 breast cancer was carried on in S.Filippo Neri 
Hospital in Rome, Italy. All patients underwent conservative 
surgery and were randomly assigned to receive IORT (10 Gy) 
and post-operatively external radiotherapy (50 Gy) or post- 
operatively external radiotherapy (50 Gy) plus a 10 Gy external 
beam boost. At the end of March 2004 234 patients have been 
randomized, 122 in IORT arm (with 127 treatments for 5 
bilateral neoplasms) and 112 in non-IORT arm. A mobile linear 
accelerator Novac7 (Hitesys SPA) was used and a dose of 10 
Gy was delivered to PTV1 including tumor volume with a radial 
margin of 2 centimeters. Electron boost was performed with 6- 
12 MeV energy beams, 10 Gys dose with one direct field on the 
scar area and the use of blocks. Clinical valuation of the 
patients was regularly made. Well balanced patient's 
characteristics were observed in the two arms about staging, 
size of tumor, histology, grading, systemic chemotherapy, 
surgical margins. 
Results: In IORT arm six cases of wound infection (4,7%) as 
acute toxicity (not significantly higher than non IORT controls) 
and 9 seromas (7,1%), regressed in 3-6 months, as late toxicity 
